Retinal neovascular diseases, such as neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular oedema (DMO), and retinal vein occlusion (RVO), are major causes of visual impairment worldwide [1,2,3]. Vascular endothelial growth factor (VEGF) is considered critical in the pathophysiology of these conditions and randomized trials have established the efficacy and safety of agents with an anti-VEGF mechanism of action [4].

视网膜新生血管疾病，如新生血管性年龄相关性黄斑变性（nAMD），糖尿病性视网膜病变（DR），糖尿病性黄斑水肿（DMO）和视网膜静脉阻塞（RVO），是全球视力障碍的主要原因[1,2,3]。血管内皮生长因子（VEGF）在这些疾病的病理生理学中被认为是至关重要的，随机试验已经确定了具有抗VEGF作用机制的药物的有效性和安全性。

Extensive real-world studies of ranibizumab or aflibercept 2 mg have also demonstrated that effectiveness in clinical practice is possible [5,6,7,8], including maintenance of vision gains through 4 years with a proactive treat-and-extend (T&E) regimen in patients with nAMD [5], and vision gains over 3 years with a meaningful reduction in treatment burden after early, consistent dosing in patients with DMO [6].Patients, physicians, and caregivers generally prefer regimens with fewer clinic visits, and although T&E regimens allow gradual treatment interval extensions once disease inactivity is verified, treatment burden to achieve optimal outcomes can remain high [9, 10].

对雷珠单抗或阿柏西普2mg的广泛现实研究也表明，临床实践中的有效性是可能的[5,6,7,8]，包括在nAMD患者中通过积极治疗和延长（T＆E）方案维持4年的视力增加[5]，以及在DMO患者早期，一致给药后3年内视力增加，治疗负担显着减轻[6]。患者，医生和护理人员通常更喜欢临床就诊次数较少的方案，尽管T＆E方案允许在疾病不活动被证实后逐渐延长治疗间隔，但达到最佳结果的治疗负担可能仍然很高[9，10]。

Consequently, many patients in real-life settings receive fewer anti-VEGF injections than administered in clinical trials, despite dosing recommendations in the regulatory-approved product label, with potentially fewer monitoring visits often resulting in suboptimal outcomes [11], leading to non-adherence and non-persistence to long-term therapy [12].To address these real-world challenges, we introduce a new concept of “sustained disease control”, which is characterized by three inter-related goals of maintaining vision gains, rapid and resilient fluid control without clinically meaningful fluctuation, and with extended treatment intervals.

因此，尽管监管部门批准的产品标签中有剂量建议，但许多在现实生活中接受抗VEGF注射的患者接受的抗VEGF注射比在临床试验中更少，监测访视可能更少，往往导致不理想的结果（11），导致不依从性和长期治疗的不持久性（12）。为了应对这些现实世界的挑战，我们引入了“持续疾病控制”的新概念，其特点是三个相互关联的目标，即保持视力提高，快速和有弹性的液体控制，没有临床意义的波动，以及延长治疗间隔。

We sugge.

我们建议。

Data availability

数据可用性

All data generated or analysed during this study are included in this published article.

本研究期间生成或分析的所有数据均包含在本文中。

ReferencesMitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147–59.Article

参考文献Mitchell P，Liew G，Gopinath B，Wong TY。年龄相关性黄斑变性。柳叶刀。2018年；392:1147-59.文章

PubMed

PubMed

Google Scholar

谷歌学者

Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Prim. 2016;2:16012.Article

Wong TY，Cheung CM，Larsen M，Sharma S，Simo R.糖尿病视网膜病变。Nat版本Dis Prim。2016年；2： 第16012条

PubMed

PubMed

Google Scholar

谷歌学者

Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Retinal vein occlusion (RVO) guideline: executive summary. Eye. 2022;36:909–12.Article

Nicholson L，Talks SJ，Amoaku W，Talks K，Sivaprasad S.视网膜静脉阻塞（RVO）指南：执行摘要。眼睛。2022年；36:909–12.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR. Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options. Clin Ophthalmol. 2022;16:917–33.Article

Tan CS，Ngo WK，Chay IW，Ting DS，Sadda SR.新生血管性年龄相关性黄斑变性（nAMD）：新兴治疗选择的回顾。临床眼科。2022年；16： 917-33.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retin. 2019;3:393–9.Article

Traine PG，Pfister IB，Zandi S，Spindler J，Garweg JG。使用“治疗和扩展”方案玻璃体内阿柏西普治疗新生血管性年龄相关性黄斑变性的长期结果。眼科视网膜蛋白。2019年；3： 393-9.文章

Google Scholar

谷歌学者

Lukic M, Williams G, Shalchi Z, Patel PJ, Hykin PG, Hamilton RD, et al. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes. Eur J Ophthalmol. 2021;31:1201–7.Article

Lukic M，Williams G，Shalchi Z，Patel PJ，Hykin PG，Hamilton RD等。现实世界中糖尿病性黄斑水肿的玻璃体内阿柏西普治疗：36个月的视力和解剖学结果。Eur J Ophthalmol。2021年；31:1201–7.文章

PubMed

PubMed

Google Scholar

谷歌学者

Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, et al. RANIBIZUMAB treatment in treatment-naive neovascular age-related macular degeneration: results from luminous, a Global real-world study. Retina. 2020;40:1673–85.Article

Holz FG，Figueroa MS，Bandello F，Yang Y，Ohji M，Dai H等。雷尼珠单抗治疗幼稚新生血管性年龄相关性黄斑变性：全球现实世界研究的结果。视网膜。2020年；40:1673–85.文章

PubMed

PubMed

Google Scholar

谷歌学者

Ashraf M, Souka AAR. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye. 2017;31:1523–36.Article

阿什拉夫M，苏卡AAR。Aflibercept在年龄相关性黄斑变性中的作用：评估其作为主要治疗选择的作用。眼睛。2017年；31:1523–36.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Loewenstein A, Sylvanowicz M, Amoaku WM, Aslam T, Cheung GCM, Eldem B et al. A global survey of patients, providers, and clinic staff from 24 countries reveals barriers to optimal care delivery for nAMD due to constraints and gaps in clinic capacity. Presented at EURETINA 2023. Available at: https://euretina.softr.app/amsterdam-abstract?recordId=rec6swwKES5yLhHNn.

Loewenstein A，Sylvanowicz M，Amoaku WM，Aslam T，Cheung GCM，Eldem B等人。对来自24个国家的患者，提供者和诊所工作人员进行的全球调查显示，由于临床能力的限制和差距，nAMD的最佳护理提供存在障碍。于2023年在EURETINA展出。网址：https://euretina.softr.app/amsterdam-abstract?recordId=rec6swwKES5yLhHNn.

Accessed January 2024.Ziemssen F, Sylvanowicz M, Amoaku wm, Aslam T, Eldem B, Finger R et al. Opportunities to improve clinical management of diabetic retinopathy and diabetic macular edema: Insights from global survey data of patients, providers, and clinic staff from 24 countries. Presented at EURETINA 2023.

2024年1月访问。Ziemssen F，Sylvanowicz M，Amoaku wm，Aslam T，Eldem B，Finger R等人。改善糖尿病视网膜病变和糖尿病黄斑水肿临床管理的机会：来自24个国家的患者，提供者和诊所工作人员的全球调查数据的见解。于2023年在EURETINA展出。

Available at: https://euretina.softr.app/amsterdam-abstract?recordId=recmlKzQAcZpAXGP0. Accessed January 2024.Ehlken C, Helms M, Bohringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13–20.Article .

网址：https://euretina.softr.app/amsterdam-abstract?recordId=recmlKzQAcZpAXGP0.2024年1月访问。Ehlken C，Helms M，Bohringer D，Agostini HT，Stahl A。AMD，DME和BRVO患者的治疗依从性与现实VA结局的关联。临床眼科。2018年；12： 。

PubMed

PubMed

Google Scholar

谷歌学者

Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234–47.Article

Okada M，Mitchell P，Finger RP，Eldem B，Talks SJ，Hirst C等。玻璃体内注射治疗新生血管性年龄相关性黄斑变性的不依从性或不持久性：混合方法系统评价。眼科学。2021年；128:234–47.文章

PubMed

PubMed

Google Scholar

谷歌学者

Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983–90.Article

Chakravarthy U，Havilio M，Syntosi A，Pillai N，Wilkes E，Benyamini G等。nAMD患者抗VEGF治疗期间黄斑液量波动对视力的影响。眼睛。2021年；35:2983–90.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118:1098–106.Article

Heier JS，Boyer D，Nguyen QD，Marcus D，Roth DB，Yancopoulos G等。CLEAR-IT 2的1年结果，这是一项血管内皮生长因子陷阱眼的2期研究，在12周固定给药后根据需要给药。眼科学。2011年；118:1098–106.文章

PubMed

PubMed

Google Scholar

谷歌学者

Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181–92.Article

Ho AC，Busbee BG，Regillo CD，Wieland MR，Van Everen SA，Li Z等。0.5 mg或2.0 mg雷珠单抗治疗中心凹下新生血管性年龄相关性黄斑变性患者的24个月疗效和安全性。眼科学。2014年；121:2181-92.文章

PubMed

PubMed

Google Scholar

谷歌学者

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.Article

Dugel PU，Koh A，Ogura Y，Jaffe GJ，Schmidt-Erfurth U，Brown DM等。HAWK和HARRIER：Brolucizumab治疗新生血管性年龄相关性黄斑变性的3期多中心随机双盲试验。眼科学。2020年；

PubMed

PubMed

Google Scholar

谷歌学者

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

。

Lancet. 2022;399:729–40.Article .

柳叶刀。2022年；399:729-40。文章。

PubMed

PubMed

Google Scholar

谷歌学者

Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141–52.Veritti D, Sarao V, Di Bin F, Lanzetta P.

Lanzetta P，Korobelnik JF，Heier JS，Leal S，Holz FG，Clark WL等。玻璃体内阿柏西普8 mg治疗新生血管性年龄相关性黄斑变性（PULSAR）：48周结果来自随机，双盲，非劣效性，3期试验。柳叶刀。2024年；。

Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics. 2023;15:1416.Article .

延长VEGF抑制增加玻璃体内阿柏西普剂量的药代动力学和药效学原理。药剂学。2023年；15： 第1416条。

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024;403:1153–63.Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al.

Brown DM，Boyer DS，Do DV，Wykoff CC，Sakamoto T，Win P等。玻璃体内阿柏西普8 mg治疗糖尿病性黄斑水肿（光子）：48周结果来自随机，双盲，非劣效性，2/3期试验。柳叶刀。2024年；403:1153–63.Wykoff CC，Brown DM，Reed K，Berliner AJ，Gerstenblith AT，Breazna A等。

Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the Phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834–42.Article .

大剂量玻璃体内阿柏西普（8 mg）对新生血管性年龄相关性黄斑变性患者的影响：CANDELA 2期随机临床试验。。2023年；141:834-42。第条。

PubMed

PubMed

Google Scholar

谷歌学者

ClinicalTrials.gov. A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced vision due to swelling in the macula, central part of the retina caused by a blocked vein in the retina (macula edema secondary to retinal vein occlusion) (QUASAR).

ClinicalTrials.gov。一项研究，旨在了解注射到眼睛中的大量阿柏西普的效果如何，以及它对由于黄斑肿胀而视力下降的人的安全性，黄斑是视网膜中央部分由视网膜静脉阻塞引起的黄斑水肿（继发于视网膜静脉阻塞的黄斑水肿）（QUASAR）。

Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05850520. Accessed January 2024.Do DV. Aflibercept 8 mg for diabetic macular edema: 2-year results of the phase 2/3 PHOTON trial. Presented at American Society of Retina Specialists 2023 Meeting. Available at: https://investor.regeneron.com/static-files/c5aea914-bada-4d6f-8742-817e319b972f.

网址：https://classic.clinicaltrials.gov/ct2/show/NCT05850520.2024年1月访问。进行DV。阿柏西普8 mg治疗糖尿病性黄斑水肿：2/3期光子试验的2年结果。在2023年美国视网膜专家学会会议上发表。网址：https://investor.regeneron.com/static-files/c5aea914-bada-4d6f-8742-817e319b972f.

Accessed January 2024.Lanzetta P, Schulze A, Schmidt-Ott U, Zhang X, Berliner A, Chu K et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the phase 3 PULSAR trial. Presented at the 23rd European Society of Retina Specialists (EURETINA) Congress.

2024年1月访问。Lanzetta P，Schulze A，Schmidt Ott U，Zhang X，Berliner A，Chu K等人。新生血管性年龄相关性黄斑变性患者的玻璃体内阿柏西普8 mg注射：第3阶段PULSAR试验的60周和96周结果。在第23届欧洲视网膜专家学会（EURETINA）大会上发表。

Available at: https://investor.regeneron.com/static-files/06016223-ff10-4fff-b9bb-3162f0ef27d9. Accessed January 2024.Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the phase 3 PULSAR trial. Presented at the Retina Society 55th Annual Scientific Meeting.

网址：https://investor.regeneron.com/static-files/06016223-ff10-4fff-b9bb-3162f0ef27d9.2024年1月访问。Korobelnik J-F。新生血管性年龄相关性黄斑变性患者的玻璃体内阿柏西普8 mg注射：3期PULSAR试验的48周结果。在视网膜学会第55届年度科学会议上发表。

Available at: https://investor.regeneron.com/static-files/d2cb2519-182f-42a6-8ac4-04544883febc. Accessed January 2024.Download referencesAcknowledgementsMedical writing and editorial support for the preparation of this manuscript (under the guidance of the authors) was provided by Afsaneh Khetrapal, BSc, of ApotheCom (UK), funded by Bayer Consumer Care AG, Basel, Switzerland, in accordance with Good Publication Pract.

网址：https://investor.regeneron.com/static-files/d2cb2519-182f-42a6-8ac4-04544883febc.2024年1月访问。下载参考文献致谢（在作者的指导下）编写本手稿的医学写作和编辑支持由ApotheCom（英国）BSc Afsaneh Khetrapal提供，由瑞士巴塞尔拜耳消费者保健公司资助，根据良好的出版实践。

PubMed Google ScholarPaolo LanzettaView author publicationsYou can also search for this author in

PubMed Google ScholarPaolo LanzettaView作者出版物您也可以在

PubMed Google ScholarCharles C. WykoffView author publicationsYou can also search for this author in

PubMed Google ScholarCharles C.WykoffView作者出版物您也可以在

PubMed Google ScholarTien Y. WongView author publicationsYou can also search for this author in

PubMed Google ScholarTien Y.WongView作者出版物您也可以在

PubMed Google ScholarXin ZhangView author publicationsYou can also search for this author in

PubMed Google ScholarXin ZhangView作者出版物您也可以在

PubMed Google ScholarPeter Morgan-WarrenView author publicationsYou can also search for this author in

PubMed Google ScholarPeter Morgan WarrenView作者出版物您也可以在

PubMed Google ScholarScott FitzpatrickView author publicationsYou can also search for this author in

PubMed Google ScholarScott FitzpatrickView作者出版物您也可以在

PubMed Google ScholarSergio LealView author publicationsYou can also search for this author in

PubMed Google ScholarSergio LealView作者出版物您也可以在

PubMed Google ScholarLynne BrunckView author publicationsYou can also search for this author in

PubMed Google ScholarLynne BrunckView作者出版物您也可以在

PubMed Google ScholarZoran HasanbasicView author publicationsYou can also search for this author in

PubMed Google ScholarZoran HasanbasicView作者出版物您也可以在

PubMed Google ScholarKaren W. ChuView author publicationsYou can also search for this author in

PubMed Google ScholarKaren W.ChuView作者出版物您也可以在

PubMed Google ScholarKimberly ReedView author publicationsYou can also search for this author in

PubMed谷歌学术评论作者出版物您也可以在

PubMed Google ScholarSobha SivaprasadView author publicationsYou can also search for this author in

PubMed Google ScholarSobha SivaprasadView作者出版物您也可以在

PubMed Google ScholarContributionsAll authors provided equal, substantial, and intellectual contribution during the writing and revising of the manuscript, and all authors approved the final version.Corresponding authorCorrespondence to

PubMed谷歌学术贡献所有作者在稿件的撰写和修订过程中提供了平等，实质性和智力上的贡献，所有作者都批准了最终版本。对应作者对应

Sobha Sivaprasad.Ethics declarations

索巴·西瓦普拉萨德。道德宣言

Competing interests

相互竞争的利益

JFK receives consulting fees from AbbVie, Apellis, Bayer, Janssen, Nano Retina, Roche, Théa Pharmaceuticals, and Carl Zeiss Meditec AG; and is a member of data and safety monitoring boards or advisory boards for Alexion, Novo Nordisk, and Oxular. PL is a consultant for Aerie, Allergan, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche.

JFK从AbbVie，Apellis，Bayer，Janssen，Nano Retina，Roche，Théa Pharmaceuticals和Carl Zeiss Meditec AG获得咨询费；并且是Alexion，Novo Nordisk和Oxular的数据和安全监控委员会或咨询委员会的成员。PL是Aerie、Allergan、Apellis、Bausch+Lomb、Bayer、Biogen、Boehringer Ingelheim、I-Care、Genentech、Novartis、Oyal Therapeutix、Outlook Therapeutics和Roche的顾问。

CCW is a consultant for 4DMT, AbbVie, Adverum, Aerie, AGTC, Alcon, Annexon, Apellis, Arrowhead, Bausch + Lomb, Boehringer Ingelheim, Cholgene, Clearside, Curacle, EyePoint, Genentech, Gyroscope, IACTA, IVERIC Bio, Janssen, Kato, Kiora, Kodiak Sciences, Kriya, Merck, Nanoscope, NGM, Novartis, Ocular Therapeutix, OcuTerra, ONL, Opthea, Oxular, Palatin, PerceiveBio, Perfuse, Ray, RecensMedical, Regeneron Pharmaceuticals, RegenXBio, Roche, and Stealth; and has received research support from 4DMT, Adverum, AffaMed, Alexion, Alimera, Alkahest, Allgenesis, Amgen, Annexin, Annexon, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Clearside, Curacle, EyePoint, Gemini, Genentech, GlaxoSmithKline, Gyroscope, IONIS, iRENIX, IVERIC bio, Kodiak Sciences, LMRI, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, Opthea, Ophthotech, Oxurion, Oxular, Oyster Point, PerceiveBio, Regeneron Pharmaceuticals, RegenXBio, Roche, and UNITY.

CCW是4DMT、AbbVie、Adverum、Aerie、AGTC、Alcon、Annexon、Apellis、Arrowhead、Bausch+Lomb、Boehringer Ingelheim、Cholgene、Clearside、Curacle、EyePoint、Genentech、陀螺仪、IACTA、IVERIC Bio、Janssen、Kato、Kiora、Kodiak Sciences、Kriya、Merck、Nanoscope、NGM、Novartis、Octera、ONL、Opthea、Oxular、Palatin、PerceiveBio、Perfusse、Ray、RecensMedical、Regeneron Pharmaceuticals的顾问RegenXBio，Roche和Stealth；并获得了4DMT，Adverum，AffaMed，Alexion，Alimera，Alkahest，Allgenesis，Amgen，Annexin，Annexon，Apellis，Asclepix，Bayer，Boehringer Ingelheim，Clearside，Curacle，EyePoint，Gemini，Genentech，GlaxoSmithKline，Gyrome，IONIS，iRENIX，IVERIC bio，Kodiak Sciences，LMRI，Nanoscope，Neurotech，NGM，Novartis，Ocular Therapeutix，OcuTerra，Opthea，Ophthotech，Oxurion，Oxular，Oyster Point等的研究支持PerceiveBio，Regeneron Pharmaceuticals，RegenXBio，Roche和UNITY。

TYW receives consulting fees from Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Genetech, Iveric Bio, Novartis, Oxurion, Plano, Roche, Sanofi, and Shanghai Henlius; and holds patents and is the cofounder of EyRiS and Visre. XZ, PMW, SL, LB, ZH and SF are employees of Bayer AG. KWC and KR are employees and stockholders of Regeneron Pharmaceuticals, Inc.

TYW从Aldropika Therapeutics，拜耳，勃林格殷格翰，Genetech，Iveric Bio，诺华，Oxurion，Plano，罗氏，赛诺菲和上海亨利士收取咨询费；。XZ、PMW、SL、LB、ZH和SF是拜耳公司的员工。KWC和KR是Regeneron Pharmaceuticals，Inc.的员工和股东。

SS is an advisor and contributes to the industry-sponso.

SS是一名顾问，为行业赞助商做出贡献。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissions

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。权限和权限

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

开放获取本文是根据知识共享署名4.0国际许可证授权的，该许可证允许以任何媒体或格式使用，共享，改编，分发和复制，只要您对原始作者和来源给予适当的信任，提供知识共享许可证的链接，并指出是否进行了更改。

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非在材料的信用额度中另有说明。如果材料未包含在文章的知识共享许可中，并且您的预期用途不受法律法规的许可或超出许可用途，则您需要直接获得版权所有者的许可。

To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/..

要查看此许可证的副本，请访问http://creativecommons.org/licenses/by/4.0/..

Reprints and permissionsAbout this articleCite this articleKorobelnik, JF., Lanzetta, P., Wykoff, C.C. et al. Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.

转载和许可本文引用本文Korobelnik，JF。，Lanzetta，P.，Wykoff，C.C。等人。使用阿柏西普8 mg持续控制疾病：视网膜新生血管疾病管理的新基准。

Eye (2024). https://doi.org/10.1038/s41433-024-03312-wDownload citationReceived: 06 August 2024Revised: 16 August 2024Accepted: 22 August 2024Published: 31 August 2024DOI: https://doi.org/10.1038/s41433-024-03312-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

眼睛（2024）。https://doi.org/10.1038/s41433-024-03312-wDownload引文收到日期：2024年8月6日修订日期：2024年8月16日接受日期：2024年8月22日发布日期：2024年8月31日OI：https://doi.org/10.1038/s41433-024-03312-wShare本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供

Subjects

主题

Quality of lifeRetinal diseases

生活质量视网膜疾病